Last Updated on October 21, 2021 by The Health Master
MSN Labs today announced that it has launched India’s most affordable Empagliflozin tablets (SGLT2i) under the brand name ‘Empaone.’
The medicine will cost Rs 15.90 and Rs 18.90 for each 10 mg and 25 mg tablet, respectively, the company informed in a statement.
‘Empaone’ is intended to provide diabetes patients in need across India with an affordable and accessible therapeutic option.
India being the diabetic capital of the world with over 77 million people suffering from type-II diabetes, this medicine will minimise the cost burden on patients and in turn improve compliance, added the statement.
It further said that the launch of Empaone ( Empagliflozin tablets) assumes critical role particularly for patients suffering from type-II diabetes and who were also affected with C-19, as diabetes has been found to be a major comorbidity factor in such cases.
MSN Group commented, “Diabetes, if not effectively managed, can lead to multiple and severe health complications.
With cost burden identified as a significant limiting factor for compliance, we are glad to launch ‘Empaone’ (Empagliflozin tablets) in a cost-effective manner making the drug available, accessible and affordable to the patients.”
MSN labs has developed the Active Pharmaceutical Ingredient (API) and the finished dosage formulation (FDF) of Empaone at its in-house state-of-the-art R&D centre.
The development is fully indigenous right from conceptualisation to API development and FDF, said the statement.
Intas launches the World’s first SB-100mg Itraconazole
West launches 0.5mL standard syringe device in India
Biocon launches Everolimus tablets in US
Natco Pharma launches higher strength Anti Cancer generic drug
Lupin launches Droxidopa capsules
Sun Pharma launches a novel formulation for Cough management
Drug alert: 42 out of 1227 samples declared as NSQ in September 2021
Drugs Technical Advisory Board (DTAB): Minutes of meetings
Govt to relax norms for Medical Devices to register with CDSCO
Govt to relax norms for Medical Devices to register with CDSCO
NPPA: Clotrimazole 1% is a Schedules formulation under DPCO 2013
3 arrested for illegal sale of Muscle Enhancing Drug
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
